ReviewDiscover oncology2024
Recent advances in early detection of nasopharyngeal carcinoma.
Review in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Primary endoscopic nasopharyngectomy for nasopharyngeal carcinoma: systematic review & meta-analysis.Frontiers in surgery · 2026Pooled it
- A Current Perspective of Two of the Most Aggressive Head and Neck Cancers: Pharyngeal and Laryngeal.Current oncology (Toronto, Ont.) · 2025Pooled it
- A closed-loop comprehensive analysis of global burden data, future projections, risk factors, and molecular mechanisms on nasopharyngeal carcinoma.International journal of surgery (London, England) · 2026Article
- Artificial intelligence in cancer diagnosis and therapy using sex and gender as precision biomarkers.Discover oncology · 2026Review
- Role of cadherin gene dysregulation in WNT signaling and nasopharyngeal carcinoma.Cell division · 2026Article
- Review
- A prognostic nomogram integrating Epstein-Barr virus DNA and specific inflammatory indices for early recurrent or metastatic nasopharyngeal carcinoma after first-line nedaplatin-based therapy.Discover oncology · 2026Article
- Pan-immune-inflammation value predicts 2-year recurrence after chemoradiotherapy in nasopharyngeal carcinoma.Frontiers in medicine · 2026Article
- Serum lactate dehydrogenase and vascular endothelial growth factor A level as a predictor of treatment response in locally advanced-stage World Health Organisation type 3 nasopharyngeal carcinoma.Contemporary oncology (Poznan, Poland) · 2026Article
- Machine learning-based prediction of nasopharyngeal carcinoma risk: a clinical approach.Frontiers in immunology · 2025Article
- Global, regional, and national burden of pediatric nasopharyngeal carcinoma (1990-2021) and projections of future disease burden trends.Frontiers in pediatrics · 2025Article
- Differentiating early-stage nasopharyngeal carcinoma from adenoidal hypertrophy via SLC40A1 expression and developing a prognostic model for disease progression.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) arises from the mucosal epithelium of the nasopharynx and is frequently located in the pharyngeal crypts. This is a highly aggressive malignant tumor that frequently leads to distant metastases in many cases and poses a significant public health challenge, particularly in certain geographic regions globally. This review discusses the epidemiology, risk factors, diagnosis, and treatment options for NPC, emphasizing the importance of early detection and comprehensive management strategies in improving patient outcomes. Moreover, the article explores the intricate mechanisms that cause NPC. Comprehending these fundamental principles can assist in creating specific prevention and therapy approaches for NPC. Recent advances in diagnostic methods, including imaging tests and molecular biomarkers, are emphasized to improve early diagnosis and individualized treatment strategies for individuals with NPC. The review also explores the most recent advancements in treating early-stage (stage I and II) NPC patients, highlighting the changing landscape of individualized therapy approaches for this particular set of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.